肝癌细胞对化疗药物的耐药性是肝癌临床疗效欠佳、复发转移的主要原因之一。探讨肝癌细胞的耐药机理不仅对深入理解肝癌发生发展的机制具有重要的理论意义，而且可为新型癌标志物及治疗性药靶分子的发现提供现实依据。CD147分子广泛参与肝癌细胞的侵袭转移、凋亡抵抗等恶性表型。项目组前期研究已发现CD147参与肝癌细胞的耐药过程，但其在作用机制尚不清楚。在前期研究的基础上，本项目拟本项目拟采用免疫共沉淀、免疫荧光、电镜、激光共聚焦、活细胞工作站、流式细胞术、染色质免疫沉淀（CHIP）、体内外功能试验等技术，结合临床肝癌临床样本分析，探究肿瘤相关膜分子CD147定位溶酶体酶解切割的机制，阐明CD147酶解切割胞内段入核调控基因表达的分子机制及其通过诱导自噬促进肝癌耐药中的作用机制，为进一步阐明肝癌的复发和耐药机制研究奠定基础，并为肝癌的临床诊治提供新的线索和靶点。

Chemotherapy resistance is the main reason for treatment failure and recurrence in patients with hepatocellular carcinoma(HCC). To explore the mechanism not only help us to deeply understand the mechanism of occurrence and development of liver cancer, but also to provide new cancer markers and therapeutic drug target molecules.CD147 is involved in the regulation of many malignant phenotype of HCC. Our previous studies showed that CD147 promotes HCC chemotherapy resistance, but the precise mechanism is still unclear. In this study, we use CoIP, immunofluorescence, electron microscope, confocal laser scan microscopy, Live cell Imaging System, Flow cytometry,CHIP, in vitro/in vivo function study and clinical example analysis techniques, to explore the mechanism of CD147 intracellular proteolysis and nuclear translocation， and the function of intracellular fragment of CD147 in gene expression regulation which is involved in chemotherapy resistance of HCC.